Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Royalty Pharma (RPRX) stock in plain English

Free brief · no signupStart here
RPRXPublished Nov 14, 2026
Royalty Pharma plc
Healthcare · Biotechnology
Funds biopharmaceutical development in exchange for future cash streams from approved therapies. Collects royalties on commercial medicines marketed by third-party pharmaceutical partners.
Assets:
Over 35 approved therapiesGenerates cash flow from commercial drugs such as Trikafta and Trelegy
New York headquartersOperates central dealmaking and management out of Manhattan offices
Around 70 employeesMaintains a concentrated team of scientific and financial professionals
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
-1.38%$67.72
$38.85B
44.1×
$2.62B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RPRX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Royalty Pharma (RPRX) do?

Royalty Pharma plc (RPRX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Funds biopharmaceutical development in exchange for future cash streams from approved therapies. Collects royalties on commercial medicines marketed by third-party pharmaceutical partners. Buys biopharmaceutical royalties directly from research institutions and inventors without running laboratory trials or. It is worth $38.85B on the market and sold $2.62B over the last year.

Market cap
$38.85B
P/E ratio
44.1×
Annual sales
$2.62B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 14, 2026

RPRX’s flags, in plain English

Each flag is a number from Royalty Pharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Wide Gross Margin

Gross margin of 99.8% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Fat Margins

Profit margin of 25.7%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Cheap on Cash Flow

Priced at 13 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Debt Is Driving

Heavy debt, 126% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about RPRX

How big is Royalty Pharma?

Royalty Pharma’s market cap is $38.85B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.62B: what customers paid the company over the last year, before any costs.

What is RPRX’s P/E ratio?

RPRX’s P/E ratio is 44.1×. Investors pay about 44.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with RPRX?

A large percentage of total royalty receipts relies on a small group of cystic fibrosis drugs marketed by Vertex. That is one risk on Royalty Pharma’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Royalty Pharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RPRX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card